



## MINNESOTA BOARD OF PHARMACY

# **Report to the Legislature on the Minnesota Insulin Safety Net Program. (In compliance with Minnesota Statutes Section 151.74, Subd. 13)**

**Data Year ending 2025**

*Aaron Patterson PharmD*

*Executive Director*

*Minnesota Board of Pharmacy*

*335 Randolph Ave, #230  
St. Paul, MN 55102*

*(651)201-2825*

*[aaron.patterson@state.mn.us](mailto:aaron.patterson@state.mn.us)*

*February 17, 2026*

## **COST OF REPORT**

Minnesota Statutes §3.197 states that a “report to the legislature must contain, at the beginning of the report, the cost of preparing the report, including any costs incurred by another agency or another level of government”. The estimated cost of preparing this report was \$500.00. That is the approximate value, in terms of salary and benefits, of the time that Board staff spent communicating with manufacturers, administering any exemptions, and preparing the report.

(The rest of this page is intentionally blank).

## Introduction

The Board of Pharmacy (Board) is submitting this report to the Legislature in compliance with Minn. Stats. §151.74, subdivision 13, which states:

Subd. 13. **Reports.** (a) By February 15 of each year, beginning February 15, 2021, each manufacturer shall report to the Board of Pharmacy the following:

- (1) the number of Minnesota residents who accessed and received insulin on an urgent-need basis under this section in the preceding calendar year;
- (2) the number of Minnesota residents participating in the manufacturer's patient assistance program in the preceding calendar year, including the number of Minnesota residents who the manufacturer determined were ineligible for their patient assistance program; and
- (3) the value of the insulin provided by the manufacturer under clauses (1) and (2).

For purposes of this paragraph, "value" means the wholesale acquisition cost (WAC) of the insulin provided.

(b) By March 15 of each year, beginning March 15, 2021, the Board of Pharmacy shall submit the information reported in paragraph (a) to the chairs and ranking minority members of the legislative committees with jurisdiction over health and human services policy and finance. The board shall also include in the report any administrative penalties assessed under subdivision 10, including the name of the manufacturer and amount of the penalty assessed.

## Reporting By Manufacturers

The total number of insulin manufacturers identified in Minnesota is six.

Manufacturers participating in the Minnesota insulin market or Insulin Safety Net Program include Eli Lilly and Company, Sanofi, and Novo Nordisk, and Biocon.

Two companies, including Baxter and MannKind provided exemption waivers from the Insulin Safety Net program as specified in Minn. Stats. §151.74, subdivision 1 (c) which states:

- (c) Any manufacturer with an annual gross revenue of \$2,000,000 or less from insulin sales in Minnesota is exempt from this section. To request a waiver under this paragraph, the manufacturer must submit a request to the Board of Pharmacy that includes documentation indicating that the manufacturer is eligible for an exemption.

All manufacturers submitted the required data and/or exemptions for calendar year 2025. The data and other information reported are provided below. The data submitted indicate that collectively the reporting manufacturers provided insulin under the Minnesota Insulin Safety Net Program to as many as **273 residents**. Since some residents may have received insulin under both the Urgent and Continuing Needs Programs, fewer total residents may have benefited.

The total value of the insulin received by residents in 2025 was **\$209,625**. (Based on the wholesale acquisition cost of the insulin – not the cost that the residents would have paid if they had purchased the insulin on their own).

All dollar amounts provided were rounded to the nearest whole dollar for this report. All notes following each reporting table were provided by that respective manufacturer.

## Eli Lilly

	2025
Urgent Need Recipients	53
Value of Insulin Provided to Urgent Need Recipients	\$16,965
	--
Continuing Need Applicants	
Total number of participants	3
Total number of ineligible applicants	3
Value of Insulin Provided to Continuing Need Recipients	\$7,284
<b>Total Value of Insulin Provided</b>	<b>\$24,249</b>

The report reflects participation in Lilly’s Minnesota patient assistance programs only. Lilly offers a number of other insulin affordability solutions for patients. Minnesota residents may have accessed Lilly insulin through Lilly’s other assistance programs, and these patients (and the value of the associated insulin) are not included in this report. Note: A patient may have applied to the continuing care program to receive more than one product or used the urgent needs program for more than one product. In those cases, the patient is counted only one time in the respective program.

The “Total number of participants” in the Lilly MN Continuing Needs Program reflects the number of unique patients who received product in 2025. This includes individuals who may have enrolled in 2024, but who continued to receive product in 2025 (when their enrollment expired), as well as new patients who enrolled in the program and received product in 2025.

Value of Insulin Provided is the WAC price of the product on the date filled by the patient.

## Novo Nordisk (Novo Nordisk Inc.)\*

	2025
Urgent Need Recipients	22
Value of Insulin Provided to Urgent Need Recipients	\$104,723
Continuing Need Applicants	
Total number of participants	13
Total number of ineligible applicants	12
Value of Insulin Provided to Continuing Need Recipients	\$34,715
<b>Total Value of Insulin Provided</b>	<b>\$139,438</b>

\*Nordisk reported two separate reports, one for each virtual manufacturer business unit registered with the board.

Novo Nordisk Pharma Inc (MN 461644)

Novo Nordisk, Inc (MN 460293)

Novo also maintains another manufacturer registered with the board as a contract manufacturer.

Novo Nordisk Pharmaceutical Industries, LP (MN 461798)

Novo Nordisk also provided an additional letter describing the company’s own Patient Assistance Program offerings. A copy of the letter directly follows this report. See *Appendix A*.

## Novo Nordisk (Novo Nordisk Pharma, Inc.)\*

	2025
Urgent Need Recipients	9
Value of Insulin Provided to Urgent Need Recipients	\$15,622
Continuing Need Applicants	
Total number of participants	0
Total number of ineligible applicants	1
Value of Insulin Provided to Continuing Need Recipients	0
<b>Total Value of Insulin Provided</b>	<b>\$15,622</b>

\*Nordisk reported two separate reports, one for each manufacturer business unit registered with the board.

Novo Nordisk Pharma Inc (MN 461644)

Novo Nordisk, Inc (MN 460293)

Novo also maintains another manufacturer registered with the board as a contract manufacturer.

Novo Nordisk Pharmaceutical Industries, LP (MN 461798)

## Sanofi

	2025
Urgent Need Recipients	165
Value of Insulin Provided to Urgent Need Recipients	\$23,855
	--
Continuing Need Applicants	
Total number of participants	3
Total number of ineligible applicants	1
Value of Insulin Provided to Continuing Need Recipients	\$1,234
<b>Total Value of Insulin Provided</b>	<b>\$25,089</b>

(1) The figures above are reflective of the Minnesota mandated programs that Sanofi offers only, and do not include data for any other Sanofi run programs. Dollars are reported as wholesale acquisition cost.

(2) Number of Minnesota residents participating in the manufacturer's patient assistance program\* in the preceding calendar year, including the number of Minnesota residents who the manufacturer determined were ineligible for their patient assistance program

\*The "manufacturer's patient assistance program" in Clause 2 is only referring to the Minnesota mandated program that Sanofi offers

\*\*The "Total number of participants" for continuing need applicants means the total number of Minnesota residents that received at least 1 shipment of product in calendar year 2025

## Biocon Biologics

	2025
Urgent Need Recipients	4
Value of Insulin Provided to Urgent Need Recipients	\$1,072
Continuing Need Applicants	
Total number of participants	1
Total number of ineligible applicants	5
Value of Insulin Provided to Continuing Need Recipients	\$4,155
<b>Total Value of Insulin Provided</b>	<b>\$5,227</b>

All Minnesota patients are reviewed under Biocon Biologics' current free drug PAP (Patient Assistance Program) eligibility criteria; however, if a patient from Minnesota does not qualify for free drug under our PAP, then that patient would be immediately reevaluated under our Minnesota Insulin Continuing Need (Safety Net) Program eligibility criteria.

## Baxter Healthcare

Baxter provided information which indicated it is exempt from the Insulin Safety Net Program. Baxter's single product offering is not a consumer insulin product and is only used intravenously via administration by licensed healthcare personnel in inpatient or urgent/emergent healthcare settings.

## MannKind

MannKind provided information which indicated it is exempt from the Insulin Safety Net Program.

## Assessment of Civil Penalties

All insulin manufacturers complied with the provisions of Minn. Stats. §151.74. The Board did not assess any civil penalties under subdivision 10.

# APPENDIX A



Jill Phillips  
Executive Director, Minnesota Board of Pharmacy  
Minnesota Board of Pharmacy  
335 Randolph Avenue, Suite #230  
St. Paul, MN 55102  
[jill.phillips@state.mn.us](mailto:jill.phillips@state.mn.us)  
[pharmacy.board@state.mn.us](http://pharmacy.board@state.mn.us)

**SENT VIA EMAIL**

February 13, 2026

## **Novo Nordisk 2025 MN Insulin Safety Net Program Reports**

Dear Executive Director Phillips,

As required under Minn. Stat. §151.74, Novo Nordisk provides the 2025 Insulin Safety Net Program Reports for the two Novo Nordisk entities that sell product in the United States, Novo Nordisk Inc. (NNI) and Novo Nordisk Pharma, Inc. (NNPI).

Through the Novo Nordisk “NovoCare®” Patient Assistance Program (PAP), Novo Nordisk offers free diabetes medication to people in need who meet certain eligibility criteria, including annual household income at or below 400% of the government-defined poverty level. The Novo Nordisk PAP existed and served patients in Minnesota prior to the passage of the Alec Smith Insulin Affordability Act (the “Act”). Novo Nordisk’s 2025 Insulin Safety Net Reports include the number of commercially insured Minnesota patients to whom we provided free insulin and who are not eligible for coverage under Novo Nordisk’s national PAP offering.

Under the Urgent Need program, pharmacists distribute product in the amount specified in the patient’s prescription. Because patient needs vary, the amount of product dispensed by a pharmacist may not be in complete packages intended for resale. Therefore, the quantity of product provided under the Urgent Need program may contain fractional number package quantities for some NDCs distributed.

Novo Nordisk continues to invest in enhancements to broaden patient access and simplify affordability support options for residents of Minnesota and patients across the United States. In

**Novo Nordisk Inc.**  
Patient Solutions Support

800 Scudders Mill Road  
Plainsboro, NJ 08536  
USA

Telephone:  
+1 609-613-1893

E-mail:  
[EZB@novonordisk.com](mailto:EZB@novonordisk.com)  
Internet:  
[www.novonordisk-us.com](http://www.novonordisk-us.com)

the US, we are expanding practical pathways to treatment across multiple channels. Through NovoCare® - our patient support program - patients can check coverage, access savings and, where eligible, receive assistance. In late 2025, we introduced direct to patient self-pay options for Wegovy® and Ozempic®.<sup>1</sup>

Kindly advise if you require any further information or would like to discuss the details of our 2025 Insulin Safety Net Program Reports.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Erik Zbranak', with a stylized flourish at the end.

Erik Zbranak

Senior Director, Market Access Channel Innovation & Operations

[EZB@novonordisk.com](mailto:EZB@novonordisk.com)

---

<sup>1</sup> Novo Nordisk Annual Report 2025, page 33, [Novo Nordisk Annual Report 2025 \(PDF\)](#).